Epidemiological analysis of SARS-CoV-2 virus infection in patients with solid tumors: The experience of Infanta Sofía University Hospital (HUIS)

ABSTRACT

Background: The global SARS-CoV-2 outbreak has significantly affected hospital assistance to cancer patients. Diagnostic and treatment paradigms have been challenged with an urgent need for patient protection. In the abscence of data to balance clinical decissions we aimed to analyze HUIS experience during the peak of the outbreak. Method(s) Cancer pts atended at HUIS since February 24th to April 24th were collected. Clinical management was adapted according to evolving international consensus. All PCR+ COVID-19 pts have been included in a database. Oncological and COVID-19 diseases characteristics as well as cancer management have been collected. The main objective of this analysis was to know the risk of SARS-CoV-2 infection, hospitalization rate and mortality of cancer patientes in our center during the outbreak and to identify potential predictive factors. Result(s) Overall, 853 cancer pts had been attended at our department during this period of time. Twenty-six pts (3.05%) were hospitalized with confirmed COVID-19 diagnosis. Underlying solid tumors were the following breast (256, 30.01%), GI (312, 36.8%), lung (100, 11.72%) and others (185, 21.47%). 322 pts (37.75%) had metastatic cancer and 531 (62.25%) had early stage diseases. 395 pts (46.31%) were treated with antineoplastic agents 62,63% received treatment as adjuvant therapy, 18. 92% as first line (or maintenance) treatment in advanced diseases and 12.81% second or following lines of treatment in advaced diseases. 10 pts (32.26%) with COVID-19 died. Futher analysis regarding clinical, laboratory and hospital risk factors - such as diagnostic procedures, type and length of treatments, number of hospital visits, etc will be reported in the final presentation. Conclusion(s) COVID-19 hospitalization rate was 3.05%, and mortality rate was 32.26%. Adequate testing and protective measures are mandatory to warrant an optimal managment of cancer pts during the global SARS-CoV-2 outbreak. Legal entity responsible for the study The authors. Funding(s) Has not received any funding. Disclosure All authors have declared no conflicts of interest. Copyright © 2020